Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) chief scientific officer Dr Valentino Parravicini speaks to Proactive after submitting a phase 1 trial application for its lead programme (OCT461201) to the UK Medicines & Healthcare products Regulatory Agency (MHRA) and Wales Research Ethics Committee (REC).
Parravicini says that the submission demonstrates that the company is "ready to go" in 2023.